Don’t Miss Out on the Latest Updates.
Subscribe to Our Newsletter Today!
- Health A-Z
- Diet & Fitness
- Home remedies
- Web Stories
Nasal Vaccine India: BBV154 may produce local antibodies in the upper respiratory tract. These may provide the potential to reduce infection and transmission, Two separate and simultaneous clinical trials were conducted, To evaluate BBV154 as a primary dose (2-dose) booster dose for subjects who have previously received 2 doses of the vaccine. Watch Video.
Enroll for our free updates
Thanks for update subscribe information